All In Biotech

Drug Trial Radar · NCT00888914

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, to Treat Moderate to Severe Lateral Canthal Lines in Adults.

Last checked: Nov 19, 2026Latest source record: Nov 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Nov 2008

Primary completion

Jan 2009

Study completion Feb 2009

Sponsor

Lead sponsor
Revance Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 28, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults.

Conditions

  • Lateral Canthal Lines
  • Crow's Feet
  • Facial Wrinkles

Interventions

  • RT001Drug

    RT001

  • RT001Drug

    RT001

  • RT001Drug

    RT001

  • RT001Drug

    RT001

  • Vehicle ComparatorOther

    Vehicle Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Smile from Baseline (Day 0) to End of Study (Day 28)Time frame: Day 28

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Richard G. Glogau, MD

    San Francisco, California

  • Head and Neck Surgical Group

    New York, New York

  • Aesthetic Plastic Surgery

    New York, New York

  • Dermatology Surgery and Laser Center

    White Plains, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.